We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
Read MoreHide Full Article
Shares of Orexigen Therapeutics Inc. crashed further 9% on Mar 12, after plummeting 76% a day before, following the news of the company filing for bankruptcy.
Orexigen’s stock has lost 77.5% in the last three months, underperforming the industry’s gain of 2.2%.
On Mar 12, Orexigen announced that it has decided to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The company also plans to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.
The bidding process is expected to conclude by May 18.
Meanwhile, Orexigen has filed a series of motions with the court thereby seeking to ensure the continuation of normal operations during this tenure. The company also has the support of a controlling number of its senior secured noteholders for this process, who have made a financing commitment of 35 million.
The news comes in the wake of an unimpressive performance of its weight-loss drug Contrave which is marketed as Mysimba in the European Union. The drug was approved by the FDA in September 2014 for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia). Accelerated commercialization efforts have increased costs and hurt the company’s profit.
Contrave is Orexigen’s only approved and marketed drug. However, being a late entrant in the obesity market, the drug faced stiff competition from products like Roche’s (RHHBY - Free Report) Xenical (orlistat) Novo Nordisk’s (NVO - Free Report) Saxenda and Arena Pharmaceuticals’s Belviq among others.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Image: Bigstock
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
Shares of Orexigen Therapeutics Inc. crashed further 9% on Mar 12, after plummeting 76% a day before, following the news of the company filing for bankruptcy.
Orexigen’s stock has lost 77.5% in the last three months, underperforming the industry’s gain of 2.2%.
On Mar 12, Orexigen announced that it has decided to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The company also plans to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.
The bidding process is expected to conclude by May 18.
Meanwhile, Orexigen has filed a series of motions with the court thereby seeking to ensure the continuation of normal operations during this tenure. The company also has the support of a controlling number of its senior secured noteholders for this process, who have made a financing commitment of 35 million.
The news comes in the wake of an unimpressive performance of its weight-loss drug Contrave which is marketed as Mysimba in the European Union. The drug was approved by the FDA in September 2014 for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia). Accelerated commercialization efforts have increased costs and hurt the company’s profit.
Contrave is Orexigen’s only approved and marketed drug. However, being a late entrant in the obesity market, the drug faced stiff competition from products like Roche’s (RHHBY - Free Report) Xenical (orlistat) Novo Nordisk’s (NVO - Free Report) Saxenda and Arena Pharmaceuticals’s Belviq among others.
Zacks Rank
Orexigen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks >>